Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06959095 · ClinicalTrials.gov registry record · Phase 3

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 3
Development phase
981
Enrollment target
15
Study locations

NCT06959095 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 981 participants, roughly in line with the 1,031-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The trial reports 15 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06959095, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 3
Development phase
981 participants
Enrollment target
15
Study locations

Study Summary

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

Conditions Studied

Pulmonary Disease, Chronic Obstructive

Interventions

  • DRUG Placebo
  • DRUG Depemokimab

Study Locations (15)

Other

  • GSK Investigational Site - Chengdu
  • GSK Investigational Site - Guangzhou
  • GSK Investigational Site - Hangzhou
  • GSK Investigational Site - Jiangmen
  • GSK Investigational Site - Jiangxi
  • GSK Investigational Site - Mianyang
  • GSK Investigational Site - Qingyuan
  • GSK Investigational Site - Zigong
  • GSK Investigational Site - Tokyo

Florida

  • GSK Investigational Site - Loxahatchee Groves
  • GSK Investigational Site - Miami

South Carolina

  • GSK Investigational Site - Rock Hill

Texas

  • GSK Investigational Site - Corsicana

Hunan

  • GSK Investigational Site - Changsha

Sichuan

  • GSK Investigational Site - Chengdu

Trial Details

FieldValue
Enrollment Target 981 participants
Start Date 2025-06-20
Est. Completion 2029-08-20
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06959095

The ClinicalTrials.gov registry entry for NCT06959095 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 981 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,031-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06959095 reports 15 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, South Carolina.

Frequently Asked Questions

What is clinical trial NCT06959095 about?

NCT06959095 is a clinical study titled "Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)". Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

What is the current status of trial NCT06959095?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 981 participants. The study started on 2025-06-20. Estimated completion is 2029-08-20.

What conditions does trial NCT06959095 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT06959095?

The interventions under investigation include: Placebo (DRUG), Depemokimab (DRUG).

Who is sponsoring clinical trial NCT06959095?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06959095 being conducted?

This trial has 15 study locations across Florida, South Carolina, Texas, Hunan, Sichuan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.